Since ACE2 is the protective axis of the RAS, soluble ACE2 shedding could exacerbate the clinical outcome of COVID-19 patients by reducing ACE2 levels on the surface of the endothelium, promoting vascular dysfunction [85,86]. The gene discussed is ACE2; the disease is COVID-19.